Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with tislelizumab and lenvatinib for pancreatic cancer liver metastases
ChiCTR2400089874Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and lenvatinib in pancreatic adenocarcinoma (PDAC) and hepatic metastasis, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Sep 2024; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)hepatic metastasis
Beyond the preview
Go deeper on ChiCTR2400089874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089874.